SCHEMBL14865648

SCHEMBL14865648

CC(C)(C#N)c1cc(-c2cncc(-c3nnc(-c4ccc(OCCN5CCCC5)cc4)o3)n2)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.43
PRKAB2 O43741 2/20 0.40
PRKAG1 P54619 2/20 0.40
PRKAA2 P54646 2/20 0.40
PRKAA1 Q13131 2/20 0.40
PRKAG3 Q9UGI9 2/20 0.40
PRKAG2 Q9UGJ0 2/20 0.40
PRKAB1 Q9Y478 2/20 0.40
TLR9 Q9NR96 3/20 0.39
TLR7 Q9NYK1 2/20 0.39
PTPN1 P18031 2/20 0.39
KDM4E B2RXH2 3/20 0.39
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14866899 0.87 ATR (0.46) LTA4H
SCHEMBL14865701 0.86 KDM4E (0.43) KDM4ENPC1ALDH1A1RAB9AHSD17B10
SCHEMBL14865852 0.85 ATR (0.45) TLR7PTPN1KDM4ENPC1ALDH1A1
SCHEMBL14865759 0.82 KDM4E (0.35) KDM4ENPC1ALDH1A1RAB9AHSD17B10
SCHEMBL14865757 0.82 RAF1 (0.41) KDM4EALDH1A1HSD17B10MAPTTSHR
SCHEMBL14865758 0.82 AXL (0.42) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL14865728 0.80 CHEK1 (0.50) BRAFACHE
SCHEMBL14865819 0.80 RAF1 (0.44) KDM4ENPC1ALDH1A1RAB9AHSD17B10
SCHEMBL14865817 0.80 RAF1 (0.36) KDM4ENPC1ALDH1A1RAB9AHSD17B10
SCHEMBL14865725 0.78 RAF1 (0.38) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 LTA4H 4319/4885PRKAB2 90/4885PRKAG1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.